Access by Design: Embedding Market Access Thinking Across the Drug Development Lifecycle
Published: | Updated:
Sponsored
As health technology assessments (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in development cycles.
